A carregar...
Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
OBJECTIVE: To assess whether canakinumab, a monoclonal antibody against IL-1β approved for autoinflammatory diseases, is effective as target-specific therapy in patients with sporadic inclusion body myositis (sIBM). METHODS: Because in sIBM IL-1β colocalizes with amyloid precursor protein and upregu...
Na minha lista:
| Publicado no: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Lippincott Williams & Wilkins
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6624107/ https://ncbi.nlm.nih.gov/pubmed/31355317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000581 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|